This anti-leukemia efficacy is associated with the simultaneous inhibition of BCL-2 by venetoclax and the downregulation of anti-apoptotic proteins or disrupting mitochondrial homeostasis, supporting that enhancing the mitochondrial pathway targeting could be a good strategy to sensitize resistant AML to venetoclax. The gene discussed is BCL2; the disease is leukemia.